A5054968300- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Gastrointestinal disorders and treatments
- Vascular Tumors and Angiosarcomas
- Neurofibromatosis and Schwannoma Cases
- Metastasis and carcinoma case studies
- Neuroscience and Neuropharmacology Research
- Amyotrophic Lateral Sclerosis Research
- Tuberous Sclerosis Complex Research
- Cardiac tumors and thrombi
- Renal cell carcinoma treatment
- Vascular Malformations and Hemangiomas
- Chronic Myeloid Leukemia Treatments
- Platelet Disorders and Treatments
- Soft tissue tumor case studies
- Receptor Mechanisms and Signaling
- Uterine Myomas and Treatments
- Soft tissue tumors and treatment
- Neuroinflammation and Neurodegeneration Mechanisms
- Alzheimer's disease research and treatments
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Glaucoma and retinal disorders
- Neurogenesis and neuroplasticity mechanisms
Fondazione IRCCS Istituto Nazionale dei Tumori
2015-2024
Institut Gustave Roussy
2021
University of Milan
2006-2021
Peter MacCallum Cancer Centre
2017
Institut Bergonié
2015
Centre Léon Bérard
2009-2015
Mario Negri Institute for Pharmacological Research
2003-2012
Université Claude Bernard Lyon 1
2012
Hôpital Européen Georges-Pompidou
2012
Hôpital de la Timone
2012
Abstract Purpose: Platelet-derived growth factor receptor-alpha (PDGFRA) mutations are found in approximately 5% to 7% of advanced gastrointestinal stromal tumors (GIST). We sought extensively assess the activity imatinib this subgroup. Experimental Design: conducted an international survey among GIST referral centers collect clinical data on patients with PDGFRA-mutant GISTs treated for disease. Results: Fifty-eight were included, 34 male (59%), and median age at treatment initiation was 61...
Purpose To report on the long-term results of a randomized trial comparing standard dose (400 mg/d) versus higher (800 imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). Patients and Methods Eligible CD117-positive GIST from 56 institutions 13 countries were randomly assigned to receive either 400 mg 800 daily. 400-mg arm allowed cross over upon progression. Results Between February 2001 2002, 946 accrued. Median age was 60 years (range, 18 91 years)....
Abstract BACKGROUND To the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT. METHODS Six patients with chordoma were treated imatinib at dose of 800 mg daily. In all patients, tumor was found to be positive PDGFRB, in four PDGFRB shown phosphorylated/expressed. RESULTS After treatment period ≥ 1 year, overt liquefaction...
In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST).Patients were randomly assigned to 2 years 400 mg daily surgery. The primary end point was overall survival; relapse-free survival (RFS), interval, and toxicity secondary points. 2009, given the concurrent improvement in prognosis advanced GIST, changed failure-free (IFFS), agreement independent data...
BACKGROUND The objectives of this study were to provide sunitinib patients with gastrointestinal stromal tumor (GIST) who otherwise unable obtain it and collect broad safety efficacy data from a large population advanced GIST after imatinib failure. (ClinicalTrials.gov identifier NCT00094029). METHODS Imatinibresistant/ intolerant received on an initial dosing schedule 50 mg daily in 6‐week cycles (4 weeks treatment, 2 off treatment). Tumor assessment frequency was according local practice,...
Abstract Purpose: Perivascular epitheliod cell tumors (PEComas) are rare mesenchymal neoplasms for which the role of systemic treatments is not established as there no published prospective clinical trials or sufficiently large retrospective case series. The aim this study to clarify activity conventional chemotherapy and biological agents in advanced/metastatic PEComas. Experimental Design: This was an observational, retrospective, international that included patients with PEComa treated...
The association between quality of surgery and overall survival in patients affected by localized gastrointestinal stromal tumors (GIST) is not completely understood.To assess the risk death with without imatinib according to microscopic margins status (R0/R1) using data from a randomized study on adjuvant imatinib.This post hoc observational included randomized, open-label, phase III trial, performed December 2004 October 2008. Median follow-up was 9.1 years (IQR, 8-10 years). at 112...
Abstract Purpose: To study the safety, tolerability, and pharmacokinetics of selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with imatinib patients advanced imatinib-resistant gastrointestinal stromal tumors. Experimental Design: A phase I intercohort dose-escalation trial was done who received either (a) 400 mg twice daily (b) escalating doses (200 once daily, qd, bid) plus bid (10- 14-hour interval daily), (c) qd. Safety, pharmacokinetics, tumor...
Few studies were conducted investigating the immunological profiles in gastrointestinal stromal tumors (GIST). Adaptive and innate immune cells are present tumor microenvironment, indicating GIST as inflamed tumors. In addition, murine models suggested a potential interaction between components imatinib. this retrospective study, profile was investigated through silico analysis immunohistochemistry (IHC), exploring basis for immunotherapy approaches. Gene expression (GEP) from 31...
Chronic treatment with asialo erythropoietin (ASIALO-EPO) or carbamylated (CEPO) improved motor behavior and reduced motoneuron loss astrocyte microglia activation in the cervical spinal cord of wobbler mice, an animal model amyotrophic lateral sclerosis, but had no effect on hematocrit values. ASIALO-EPO CEPO, like parent compound EPO, protected primary cultures from kainate-induced death vitro. Both EPO receptor common CD131 β chain were expressed cultured motoneurons anterior horn mice...
Quadruple wild-type (WT) gastrointestinal stromal tumor (GIST) is a genomic subgroup lacking KIT/PDGFRA/RAS pathway mutations, with an intact succinate dehydrogenase (SDH) complex. The aim of this work to perform wide comprehensive study on quadruple WT GIST improve the characterization these patients. We selected 14 clinical cases GIST, which nine showed sufficient DNA quality for whole exome sequencing (WES). NF1 alterations were identified directly by WES. Gene expression from...
The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, association dose and other clinicopathologic variables was evaluated a large multi-institutional European cohort.Data from 185 were retrospectively collected 23 GIST reference centers. Propensity score matching (PSM) inverse-probability weighting (IPTW) used to account for confounders. Univariate...
The synthesis, pharmacological evaluation, and structure−activity relationships (SARs) of a series novel arylalkylpiperazines structurally related to BP897 (3) are described. In binding studies, the new derivatives were tested against panel dopamine, serotonin, noradrenaline receptor subtypes. Focusing mainly on dopamine D3 receptors, SAR studies brought light number structural features required for high affinity selectivity. Several heteroaromatic systems explored their affinities,...
10500 Background: In 2004 we launched an open-label randomized trial with adjuvant IM for 2 yrs in localized, surgically resected, high/intermediate-risk GIST. Methods: Pts were between of IM, 400 mg daily, and no further therapy after surgery. The primary end-point was OS, while RFS, RFI toxicity secondary end-points. Main eligibility criteria were: age >18 yrs, PS 0-2, localized CD117-positive GIST, intermediate or high risk according to the 2002 Consensus classification, R0 R1 surgical...